As you are aware, the MedTech industry in India, is facing a rapidly changing healthcare ecosystem, with constant epidemiological shifts, changing regulatory and policy environments, increasing healthcare cost containment pressures, and evolving reimbursement systems that are all key drivers impacting patient access to medical devices. In this COVID-19 era, the need for healthcare systems change is very real, which is where technology and its evaluation plays a major role. Through this Webinar our intent is to understand how medical technologies should be evaluated, from a global perspective which will enable a more robust and nuanced policy framework on the technology assessment in India.
Key Discussion Points
- The independence of HTA agencies is required to enable independent reviews, lend greater transparency, and bring broader perspectives to the HTA assessment process.
- The coherence between HTA body, Regulatory, and Public reimbursement/coverage bodies to reduce uncertainty in product development for manufacturers and increase access to new technologies (including digital health technologies).
- All stakeholders should have reasonable access to the HTA process, including inputs from specialists in therapy areas
- HTA should be fit for purpose and take into account the key issues that differentiate medical devices from pharmaceuticals.
- HTA must act as a fulcrum of evidence-based and clinico-economic decision making in India in case of novel technologies
Who Should Attend
- MTAB and Government agencies from Department of Health Research
- Thought leaders and academic institutions who are involved in HTA research and policy directions
- Payors – Reimbursement (IRDA, NHA, State reimbursement agencies) and procurement agencies (HLL Lifecare)
- Industry – Medical Devices and Pharmaceuticals Companies
- HTA Nodal Bodies/Institutions and Hospital Chain Leaders